Percentage of uncertain income tax position Percentage Of Uncertain Income Tax Position Percentage of uncertain Income tax position. Net working capital Workings Capital Represent the amount of workings capital. Incorporated date Entity Incorporation, Date of Incorporation Description of Business and Summary of Significant Accounting Policies [Abstract] Cash and cash equivalents Cash and Cash Equivalent Cash balances insured amount Cash, FDIC Insured Amount Cash used in operations Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net loss Net loss and comprehensive loss Description of Business and Summary of Significant Accounting Policies New Accounting Pronouncements or Change in Accounting Principle [Line Items] Operating segment Number of Operating Segments Reportable segment Number of Reportable Segments Non-cash expenses Other Noncash Expense Accumulated deficit Retained Earnings (Accumulated Deficit) Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Description of CODM Segment Reporting, Expense Information Used by CODM, Description Fair Value Measurements - Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements (Details) [Table] Financial Assets [Abstract] Asset Purchase Agreement (Details) [Table] Product and Service [Domain] Sale of Stock [Axis] Veralox Therapeutics Inc. [Member] Veralox Therapeutics Inc Member Statistical Measurement [Domain] Maximum [Member] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Veralox APA [Member] Veralox APAMember Related Party Transaction [Domain] Haisco Licensing Agreement [Member] Haisco Licensing Agreement Member Consideration purchase of assets Payments for Purchase of Other Assets Annual net sales percentage Seller Royalties Percentage Seller royalties percentage. License agreement amount Revenues Royalty expense Royalty Expense First Patient Dosed in Phase 1 Initiated with EP-7327 [Member] First Patient Dosed In Phase1 Initiated With EP7327 Member FDA Approval of New Drug Application for Frunexian or EP-7327 [Member] FDAApproval Of New Drug Application For Frunexian Or EP7327 Member First regulatory filing approval to market a pharmaceutical product for human use containing a Compound that is covered by a patent owned or licensed by Veralox (the “Product”) in the United States [Member] First USFDAApproval For Seller Patented Verilox Product Member Regulatory filing approval to market a Product for a subsequent indication in the United States [Member] Regulatory Filing Approval To Market AProduct For ASubsequent Indication In The United States Member Schedule of Contingent Milestone Payments [Line Items] Asset Purchase Agreement [Abstract] Product and Service [Axis] Royalty [Member] Royalty [Member] Sale of Stock [Domain] Statistical Measurement [Axis] Minimum [Member] Minimum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Asset Purchase Agreement Member Related Party Transaction [Axis] eXIthera Pharmaceuticals, Inc. [Member] e XIthera Pharmaceuticals Inc Member Asset Purchase Agreement [Line Items] Schedule of Initial Purchase Price of the Assets Acquired [Line Items] Consideration asset Total Asset Acquisition, Consideration Transferred Direct transaction costs Direct Operating Costs Royalty revenue received Royalty Revenue Received Amount of revenue received from royalty. Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Financial Assets: Assets [Abstract] Total financial assets Assets, Fair Value Disclosure Schedule of Accrued Liabilities [Abstract] Accrued research and development Accrued Research And Development Accrued research and development. Other Other Accrued Liabilities, Current First Patient Dosed in the First Clinical Trial with CAD-1005 [Member] First Patient Dosed In The First Clinical Trial With CAD1005 Member First regulatory filing approval to market a Product outside the United States [Member] First Regulatory Filing Approval To Market AProduct Outside The United States Member Regulatory filing approval to market a Product for a subsequent indication outside the United States [Member] Regulatory Filing Approval To Market AProduct For ASubsequent Indication Outside The United States Member Milestone payment Payments Of Milestones The amount represents payments of milestones. First Patient Dosed in Phase 2 Initiated with Frunexian or EP-7327 [Member] First Patient Dosed In Phase2 Initiated With Frunexian Or EP7327 Member 2025 Shares [Member] Two Thousand Twenty Five Shares [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Expire date Warrants and Rights Outstanding, Maturity Date Outstanding, Ending Outstanding, Beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule Of Assumptions Used In Black Scholes Model Abstract Class of Warrant or Right [Axis] Stockholders’ Equity [Line Items] Common stock, par value (in Dollars per share) Common Stock, Par or Stated Value Per Share Preferred stock, par value (in Dollars per share) Preferred stock par value (in Dollars per share) Preferred Stock, Par or Stated Value Per Share Number of shares Proceeds from sale of common stock under the ATM, net of issuance costs (in Shares) Stock Issued During Period, Shares, New Issues Offering price Sale of Stock, Price Per Share Exercise price per share Exercise Price Per Share (in Dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Equity-Based Compensation (Details) [Table] Plan Name [Domain] Equity Components [Axis] Common Stock [Member] Common Stock Common Stock [Member] Maximum number of shares of common stock Maximum Number Of Shares Of Common Stock Maximum number of shares of common stock. Percentage of common stock outstanding Common Stock Outstanding Percentage The percentage of common stock outstanding percentage. Common stock award shares Stock Issued During Period, Shares, Period Increase (Decrease) Remained shares available for future issuance Remained Available Shares For Future Issuance Remained available shares for future issuance. Weighted average grant date fair value of options granted (in Dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Schedule Of Initial Purchase Price Of The Assets Acquired Abstract Class of Warrant or Right [Table] Financial Instruments [Domain] Placement agent warrants [Member] Placement Agent Warrant One Member New Series B-1 warrants [Member] New Series B-2 warrants [Member] New Series B-2 Warrants [Member] Placement agent warrants [Member] Placement Agent Warrants Five [Member] Pre-funded warrants [Member] Pre-Funded Warrants [Member] New Series C-1 warrants [Member] New Series C-1 Warrants [Member] New Series C-2 warrants [Member] New Series C-2 Warrants [Member] Placement agent warrants [Member] Placement Agent Warrants Six [Member] June 2026 Warrant Issuance [Member] June Two Thousand Twenty Six Warrant Issuance [Member] April 2026 Warrant Inducement [Member] April Two Thousand Twenty Six Warrant Inducement [Member] Purchase up to shares Class of Warrant or Right, Number of Securities Called by Warrants or Rights Purchase price per share Shares Issued, Price Per Share Pre-funded Warrants [Member] Pre-Funded Warrant [Member] Series C-1 Warrants [Member] Series C-1 Warrant [Member] Common Warrants [Member] Series C-1 Warrants and Series C-2 Warrants [Member] Placement Agent Warrant [Member] Percentage of pre-funded warrant shares Percentage of Pre-Funded Warrant Shares Percentage of pre-funded warrant shares. Existing Warrants [Member] Existing Warrant [Member] Inducement Agreement [Member] Series B-1 Warrants [Member] Series B-1 Warrant [Member] New Warrant [Member] Aggregate gross proceeds Proceeds from Warrant Exercises Other expenses Other Expenses ATM Facility [Member] Weighted average price per share Options granted (in Dollars per share) Weighted-Average Exercise Price Per Share, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Total gross proceeds Proceeds from sale of common stock under ATM Proceeds from Issuance of Common Stock Series C-2 Warrants [Member] Series C-2 Warrant [Member] Anniversary date Anniversary Date Anniversary date. Exercisable term Exercisable Term Exercisable term. Stock options to purchase common stock [Member] Schedule of Common Stock Equivalents were Excluded from the Calculation of Diluted Net Loss Per Share [Line Items] Total anti-dilutive common stock equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Future Annual Lease Payments Under Non-Cancellable Operating Leases [Abstract] Total lease payments Lessee, Operating Lease, Liability, to be Paid Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Warrants to purchase common stock [Member] Warrant [Member] Anti-dilutive common stock equivalents: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Line Items] Document Fiscal Period Focus Document Information [Line Items] Document Quarterly Report Entity Interactive Data Current Document Fiscal Year Focus Amendment Flag Gross proceeds Gross proceeds Proceeds from Issuance of Private Placement Statement Income Location Balances [Domain] Statement of Income Location Balances [Axis] General and administrative [Member] General And Administratives [Member] Research and development [Member] Research And Developments [Member] Cash paid for office lease Increase (Decrease) in Operating Liabilities Weighted-Average Remaining Contractual Life (Years), Outstanding balance Weighted-Average Remaining Contractual Life (Years), Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Number Outstanding, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Entity Address, Address Line Two Entity Address, State or Province Entity Address, Postal Zip Code Pre-Funded Warrants [Member] Pre Funds Warrants [Member] Series C-1 Warrants [Member] Series C One Warrant [Member] Series C-2 Warrants [Member] Series C Two Warrant [Member] Weighted-Average Remaining Contractual Life (Years), Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term Class of Warrant or Right [Domain] Subsequent Events [Abstract] Security Exchange Name Number Outstanding, Options vested and expected to vest Number Outstanding, Outstanding balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance Subsequent Events (Details) [Table] Entity Registrant Name Entity Tax Identification Number Entity Filer Category Entity Shell Company Entity Ex Transition Period Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule of Activity Under the Plans [Abstract] Weighted-Average Exercise Price Per Share, Outstanding balance Weighted-Average Exercise Price Per Share, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Total liabilities Liabilities Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Total stockholders’ equity Balance Balance Equity, Attributable to Parent Preferred stock, shares issued (in Shares) Preferred Stock, Shares Issued Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense Total operating expenses Operating Expenses Common stock, shares issued (in Shares) Common Stock, Shares, Issued Total other income Nonoperating Income (Expense) Net loss per common share, basic (in Dollars per share) Net loss per common share, basic Earnings Per Share, Basic Weighted average number of common shares used in computing net loss per common share, basic (in Shares) Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Other assets Other Assets, Noncurrent Current liabilities: Liabilities, Current [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Total current liabilities Liabilities, Current Stockholders’ equity: Stockholders’ Equity [Abstract] Common stock, $0.001 par value; 75,000,000 shares authorized, 3,098,592 shares issued and outstanding as of June 30, 2026; 2,338,127 shares issued and outstanding as of December 31, 2025 Common Stock, Value, Issued Total liabilities and stockholders’ equity Liabilities and Equity Statement of Financial Position [Abstract] Preferred stock, shares authorized (in Shares) Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares outstanding (in Shares) Preferred Stock, Shares Outstanding Common stock, shares authorized (in Shares) Common stock, shares authorized Common Stock, Shares Authorized Income Statement [Abstract] General and administrative expenses General and Administrative Expense Depreciation expense Depreciation Loss from operations Operating Income (Loss) Common stock, shares outstanding (in Shares) Common Stock, Shares, Outstanding Interest and dividend income Investment Income, Interest and Dividend Net loss per common share, diluted (in Dollars per share) Net loss per common share, diluted Earnings Per Share, Diluted Weighted average number of common shares used in computing net loss per common share, diluted (in Shares) Weighted Average Number of Shares Outstanding, Diluted Statement of Stockholders' Equity [Abstract] Additional Paid-In Capital Additional Paid-in Capital [Member] Equity Component [Domain] Equity-based compensation - options APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Issuance of common stock for consulting services (in Shares) Stock Issued During Period, Shares, Issued for Services Proceeds from sale of common stock, net issuance costs Proceeds from Debt, Net of Issuance Costs Acquisitions Acquisitions Policy Text Block Disclosure of accounting policy for acquisitions. Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Assumptions Used in Black-Scholes Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Accrued Liabilities [Abstract] Schedule of Development Milestones Schedule Of Development Milestones Table Text Block Trading Symbol Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Statement of Cash Flows [Abstract] Interest receivable Increase (Decrease) in Accrued Interest Receivable, Net Deferred offering costs Increase (Decrease) in Deferred Charges Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Proceeds from exercise of stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash and cash equivalents – beginning of the period Cash and cash equivalents – end of the period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Description of Business and Summary of Significant Accounting Policies Business Description and Accounting Policies [Text Block] Recent Accounting Pronouncements [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Asset Purchase Agreement Other Assets Disclosure [Text Block] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Net Loss Per Share [Abstract] Leases, Commitments, and Contingencies Leases Commitments And Contingencies Text Block The tabular disclosure of leases commitments and contingencies. Accrued liabilities Increase (Decrease) in Accrued Liabilities Disposal of property & equipment Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from warrant inducements Proceeds from Issuance of Warrants Issuance costs from warrant inducement Proceeds from Issuance Costs Warrant Inducement Represent the amount of issuance costs warrant inducement. Supplemental disclosure of non-cash financing activities: Supplemental Cash Flow Information [Abstract] Current assets: Assets, Current [Abstract] Interest receivable Interest Receivable, Current Deferred offering costs Deferred Costs, Current Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Cash flows used in operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Prepaid expenses Increase (Decrease) in Prepaid Expense Accounts payable Increase (Decrease) in Accounts Payable Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Investment in property and equipment Payments to Acquire Property, Plant, and Equipment Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Fair Value Measurements [Abstract] Schedule of Equity-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Common Stock Equivalents were Excluded from the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Basic and Diluted Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Leases, Commitments, and Contingencies [Abstract] Schedule of Future Annual Lease Payments Under Non-Cancellable Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Description of Business and Summary of Significant Accounting Policies [Table] First Patient Dosed in Phase 3 Initiated with Frunexian or EP-7327 [Member] First Patient Dosed In Phase3 Initiated With Frunexian Or EP7327 Member Fair Value Hierarchy and NAV [Domain] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Schedule of Financial Assets and Liabilities Subject to Fair Value Measurements [Line Items] Money market funds Cash Equivalent, Money Market Fund, Carrying Value Accrued compensation Accrued Employee Benefits, Current Accrued professional fees Accrued Professional Fees, Current Schedule Of Development Milestones Abstract Accrued severance Represent the amount of accrued severance. Asset Purchase Agreement - Schedule of Development Milestones (Details) [Table] Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Stockholders’ Equity (Details) [Table] Class of Stock [Domain] Private Placement [Member] Private Placement [Member] Common stock vote held Common Stock, Voting Rights Sold shares Sale of Stock, Number of Shares Issued in Transaction Expire term Warrants and Rights Outstanding, Term Net proceeds Net Proceeds Net proceeds. Equity-Based Compensation [Abstract] Plan Name [Axis] 2022 Plan [Member] Two Thousand Twenty Two Plan Member Equity-Based Compensation [Line Items] Calendar year Calendar Year Calendar year. Percentage of reserved shares of common stock available for issuance Reserved Shares Of Common Stock Available For Issuance Reserved shares of common Stock available for issuance. Unrecognized stock-based compensation expense (in Dollars) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Placement agent warrants [Member] Placement Agent Warrants Two Member New Series A-2 warrants [Member] New Series A2 Warrants Member Investor Warrants 2025 [Member] Investor Warrants2025 Member Schedule of Total Warrants Outstanding [Line Items] Weighted average remaining requisite service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Asset Acquisition [Table] eXIthera APA [Member] e XIthera APAMember Financial Instrument [Axis] Placement agent warrants [Member] Placement Agent Warrants Member Representative Warrants [Member] Representative Warrants Member New Series A-1 warrants [Member] New Series A1 Warrants Member Placement agent warrants [Member] Placement Agent Warrants Three Member Placement agent warrants [Member] Placement Agent Warrants Four Member Issue Date Class Of Warrant Or Right Issue Date Issue Date. Expiration Date Class Of Warrant Or Right Expiration Date Expiration Date. New Issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Exercised Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Equity-Based Compensation - Schedule of Assumptions Used in Black-Scholes Model (Details) [Table] In process research and development Asset Acquisition Consideration Transferred In Process Research And Development Amount of transaction cost incurred in process research and development. Schedule Of Total Warrants Outstanding Abstract Class of Stock [Axis] 2025 Common Warrants [Member] Twenty Twenty Five Common Stock Member 2025 Common Warrant Shares [Member] Two Thousand Twenty Five Common Warrant Shares [Member] Document Period End Date Weighted-Average Exercise Price Per Share, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Aggregate Intrinsic Value, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number Outstanding, Exercised Stock Issued During Period Shares Stock Option Exercised Number of share options (or share units) exercised during the current period. Aggregate Intrinsic Value, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted-Average Exercise Price Per Share, Canceled/forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Equity-Based Compensation Expense [Line Items] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities, Name [Domain] Lease to extend term Lessee, Finance Lease, Term of Contract Operating lease expenses Operating Lease, Expense Aggregate Intrinsic Value, Outstanding balance Aggregate Intrinsic Value, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Weighted-Average Exercise Price Per Share, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Aggregate Intrinsic Value, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Information [Table] Document Type Document Transition Report Entity Central Index Key Current Fiscal Year End Date Entity Current Reporting Status Entity File Number Entity Emerging Growth Company Entity Small Business Local Phone Number Title of 12(b) Security Entity Incorporation, State or Country Code Pre-Funded Warrant Agreement [Member] Schedule of Assumptions Used in Black-Scholes Model [Line Items] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number Outstanding, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted-Average Remaining Contractual Life (Years), Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Number Outstanding, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Aggregate Intrinsic Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted The amount of aggregate intrinsic value granted. Weighted-Average Exercise Price Per Share, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number Outstanding, Canceled/forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Aggregate Intrinsic Value, Canceled/forfeited/expired Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Forfeited Expired The amount of aggregate intrinsic value canceled/forfeited/expired. Schedule Of Equity Based Compensation Expense Abstract Total equity-based compensation expense Share-Based Payment Arrangement, Expense Schedule Of Basic And Diluted Net Loss Per Common Share Abstract Net loss Net Income (Loss) Available to Common Stockholders, Basic Schedule Of Common Stock Equivalents Were Excluded From The Calculation Of Diluted Net Loss Per Share Abstract Antidilutive Securities [Axis] Entity Address, Address Line One Entity Address, City or Town City Area Code Entity Common Stock, Shares Outstanding Cover [Abstract] Stockholders’ Equity Equity [Text Block] Net Loss Per Share Earnings Per Share [Text Block] Subsequent Events Subsequent Events [Text Block] Emerging Growth Company Status Emerging Growth Company Status Policy Text Block Disclosure of accounting policy emerging growth company status. Liquidity Liquidity Policy Text Block Disclosure of accounting policy for liquidity. Concentration of Credit and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Deferred Offering Costs Deferred Offering Costs Policy Text Block Disclosure of accounting policy for deferred offering costs. Receivable from issuance of warrants Receivable from issuance of warrant The amount of receivable from issuance of warrants. Total assets Assets Accounts payable Accounts Payable, Current Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Issuance costs under accrued expenses Issuance Costs Under Accrued Expenses The amount of issuance costs under accrued expenses. Issuance costs for sale of common stock under ATM Payment of Financing and Stock Issuance Costs, Total Statement [Table] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Balance (in Shares) Balance (in Shares) Shares, Outstanding Issuance of common stock for consulting services Stock Issued During Period, Value, Issued for Services Proceeds from sale of common stock under the ATM, net of issuance costs Stock Issued During Period, Value, New Issues Income Taxes Income Tax, Policy [Policy Text Block] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Patents Patent Policy Text Block Disclosure of accounting policy for Patent. Other income Nonoperating Income (Expense) [Abstract] Schedule of Total Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Activity Under the Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Initial Purchase Price of the Assets Acquired Asset Acquisition [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Receivable from issuance of warrants Represent the amount of receivable from issuance of warrants. Proceeds from warrant inducements, net of issuance costs Stock Issued During Period Value Proceeds from Warrant Inducements Net of Issuance Costs Value of stock issued proceeds from warrant inducements net of issuance costs. Proceeds from warrant inducements, net of issuance costs (in Shares) Stock Issued During Period Shares Proceeds from Warrant Inducements Net of Issuance Costs Number of shares issued proceeds from warrant inducements net of issuance costs. Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (in Shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Proceeds from warrant issuances, net of issuance costs Adjustments to Additional Paid in Capital, Warrant Issued Proceeds from warrant issuances, net of issuance costs Stock Issued During Period, Value, Other Proceeds from warrant inducements, net issuance costs Net of issuance costs Amount of net of issuance costs. Other assets Increase (Decrease) in Other Operating Assets, Total Chief Executive Officer